

# AKBA

**Catalog No: tcsc3736**



## Available Sizes

**Size:** 5mg

**Size:** 10mg



## Specifications

**CAS No:**

67416-61-9

**Formula:**

$C_{32}H_{48}O_5$

**Pathway:**

Metabolic Enzyme/Protease

**Target:**

HIF/HIF Prolyl-Hydroxylase

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 5.2$  mg/mL (10.14 mM)

**Alternative Names:**

Acetyl-11-keto- $\beta$ -boswellic acid

**Observed Molecular Weight:**


512.72

## Product Description

Acetyl-11-Keto- $\beta$ -Boswellic Acid (AKBA) is an active triterpenoid compound from the extract of *Boswellia serrate*; a novel Nrf2 activator.

Target: Nrf2 activator

in vivo: AKBA significantly prevented the formation of intestinal adenomatous polyps without toxicity to mice. AKBA's activity both in the prevention of small intestinal and colonic polyps was more potent than aspirin. Histopathologic examination revealed that AKBA's effect, that is the reduction of polyp size and degree of dysplasia, was more prominent in larger sized polyps, especially those originating in colon [2]. AKBA administration in mice effectively delayed the growth of HT-29 xenografts without signs of toxicity. The activity of AKBA was more potent than that of aspirin [3]. AKBA exhibited anti-cancer activity in vitro and in vivo. With oral application in mice, AKBA significantly inhibited SGC-7901 and MKN-45 xenografts without toxicity [4].



Copyright 2021 Taiclone Biotech Corp.